Scribd Logo
Upload

Welcome to Scribd!

  • 31 views

    Ilmiah Tahunan 2001. Jakarta. Pusat Informasi Dan Penerbitan

    Uploaded by

    Imasari Aryani
    1. The document discusses several studies on thrombocytopenia in the context of chronic liver disease and cirrhosis. 2. Thrombocytopenia is a common complication of chronic liver disease and can result from impaired platelet production and decreased liver function. 3. Multiple factors are involved in the pathophysiology of thrombocytopenia in chronic liver disease, including portal hypertension, hypersplenism, impaired thrombopoietin production and platelet clearance.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Ilmiah Tahunan 2001. Jakarta. Pusat Informasi Dan Penerbitan

    Uploaded by

    Imasari Aryani
    31 views6 pages
    1. The document discusses several studies on thrombocytopenia in the context of chronic liver disease and cirrhosis. 2. Thrombocytopenia is a common complication of chronic liver disease and can result from impaired platelet production and decreased liver function. 3. Multiple factors are involved in the pathophysiology of thrombocytopenia in chronic liver disease, including portal hypertension, hypersplenism, impaired thrombopoietin production and platelet clearance.

    Original Description:

    interna

    Original Title

    dafpus

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    1. The document discusses several studies on thrombocytopenia in the context of chronic liver disease and cirrhosis. 2. Thrombocytopenia is a common complication of chronic liver disease and can result from impaired platelet production and decreased liver function. 3. Multiple factors are involved in the pathophysiology of thrombocytopenia in chronic liver disease, including portal hypertension, hypersplenism, impaired thrombopoietin production and platelet clearance.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    31 views6 pages

    Ilmiah Tahunan 2001. Jakarta. Pusat Informasi Dan Penerbitan

    Uploaded by

    Imasari Aryani
    1. The document discusses several studies on thrombocytopenia in the context of chronic liver disease and cirrhosis. 2. Thrombocytopenia is a common complication of chronic liver disease and can result from impaired platelet production and decreased liver function. 3. Multiple factors are involved in the pathophysiology of thrombocytopenia in chronic liver disease, including portal hypertension, hypersplenism, impaired thrombopoietin production and platelet clearance.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 6

    Akbar N. Diagnosis dan penatalaksanaan hepatitis autoimun.

    Pertemuan

    Ilmiah Tahunan 2001. Jakarta. Pusat Informasi dan Penerbitan

    Bagian Penyakit Dalam FKUI. Hal 27-29

    Amirudin R. 2007. Fibrosis Hati. Dalam : Sulaiman A. Akbar HN.

    Lesmana LA. Noer MS. Buku Ajar Ilmu Penyakit Hati 1. Jakarta:

    Penerbit Jayabadi

    Cantor SB, Elting LS, Hudson Jr DV. Rubenstein EB. Pharmacoeconomic

    analysis of oprelvekin (recombinant human interleukin-11) for

    secondary prophylaxis of thrombocytopenia in solid tumor patients

    receiving chemotherapy. Cancer 2003;97:3099–3106.

    Davis GL. Hepatitis C. In: Shiff ER (eds). Shiff’s Diseases of the liver.

    11th ed. Philadeplhia: Lippincott; 2011.p.757-91.

    Evstatiev R, Bukaty A, Jimenez K, et al. Iron deficiency alters

    megakaryopoiesis and platelet phenotype independent of

    thrombopoietin. Am J Hematol. 2014;89(5):524–529.

    George JN. Idiopathic thrombocytopenic purpura: current issues for

    pathogenesis, diagnosis, and management in children and adults. Curr

    Hematol Rep 2003;2:381–387.

    Hayashi H, Beppu T, Shirabe K, et al. Management of thrombocytopenia

    due to liver cirrhosis: a review. World J Gastroenterol. 2014;20(10):

    2595–2605.
    Jaroszewicz J, Rogalska M, Flisiak R. Serum prohepcidin reflects the

    degree of liver function impairment in liver cirrhosis. Biomarkers.

    2008;13(5):478–485.

    Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of

    thrombocytopenia in chronic liver disease. Hepatic Medicine :

    Evidence and Research. 2016;8:39-50. doi:10.2147/HMER.S74612.

    Oxford Medical Education. 2015. Chronic Liver Disease-Compensated.

    Perrotta PL, Snyder EL. Non-infectious complications of transfusion

    therapy. Blood Rev 2001;15:69–83.

    Price SA & Wilson LM. Transliterasi Penlit, Brahm U, dr. dkk. 2005.

    Patofisiologi. Jakarta: EGC.

    Sembiring J (2009). Korelasi kadar thrombopoietin serum dengan fibrosis

    hati pada penderita hepatitis kronik. Diss; 1-16

    Sheikh MY, Raoufi R, Atla PR, et al. Prevalence of cirrhosis in patients

    with thrombocytopenia who receive bone marrow biopsy. Saudi J

    Gastroenterol. 2012;18(4):257–262.

    Sherlock S, Dooley J. Drugs and the liver. In: Diseases of the liver and

    billiary system. 12th ed. London: Blackwell; 2011.p.322-356

    Suyono S, dkk. 2001. Buku ajar ilmu penyakit dalam jilid II edisi ketiga.

    Jakarta: EGC.

    Tsukada S, Parsons CJ, Rippe RA (2006). Mechanism of Liver fibrosis.

    Clinica Chimica Acta; 364: 33-60

    2
    Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of

    ADAMTS13 in patients with liver cirrhosis. Thromb Haemost.

    2008;99(6):1019–1029.

    Uemura M, Fujimura Y, Ko S, et al. Pivotal role of ADAMTS13 function

    in liver diseases. Int J Hematol. 2010;91(1):20–29.

    Venkata C, Kashyap R, Farmer JC, et al. Thrombocytopenia in adult

    patients with sepsis: incidence, risk factors, and its association with

    clinical outcome. J Intensive Care. 2013;1(1):9.

    Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol

    Clin North Am. 2007;21(4):685–696, vi.

    Wang CS, Yao WJ, Wang ST, et al. Strong association of hepatitis C virus

    (HCV) infection and thrombocytopenia: implications from a survey of

    a community with hyperendemic HCV infection. Clin Infect Dis.

    2004;39(6):790–796.

    Weksler BB. Review article: the pathophysiology of thrombocytopenia in

    hepatitis C virus infection and chronic liver disease. Aliment Phar-

    macol Ther. 2007;26(Suppl 1):13–19.

    Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha 2b-induced

    thrombocytopenia is caused by inhibition of platelet production but not

    proliferation and endomitosis in human megakaryocytes. Blood.

    2008;112(3):542–550.

    3
    1. Oxford Medical Education. 2015. Chronic Liver Disease-
    Compensated.
    2. Amirudin R. 2007. Fibrosis Hati. Dalam : Sulaiman A. Akbar HN.

    Lesmana LA. Noer MS. Buku Ajar Ilmu Penyakit Hati 1. Jakarta:

    Penerbit Jayabadi

    3. Suyono S, dkk. 2001. Buku ajar ilmu penyakit dalam jilid II edisi

    ketiga. Jakarta: EGC.

    4. Davis GL. Hepatitis C. In: Shiff ER (eds). Shiff’s Diseases of the liver.

    11th ed. Philadeplhia: Lippincott; 2011.p.757-91.

    5. Hayashi H, Beppu T, Shirabe K, et al. Management of

    thrombocytopenia due to liver cirrhosis: a review. World J

    Gastroenterol. 2014;20(10): 2595–2605.

    6. Sherlock S, Dooley J. Drugs and the liver. In: Diseases of the liver and

    billiary system. 12th ed. London: Blackwell; 2011.p.322-356

    7. Tsukada S, Parsons CJ, Rippe RA (2006). Mechanism of Liver

    fibrosis. Clinica Chimica Acta; 364: 33-60

    8. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology

    of thrombocytopenia in chronic liver disease. Hepatic Medicine :

    Evidence and Research. 2016;8:39-50. doi:10.2147/HMER.S74612.

    9. Sheikh MY, Raoufi R, Atla PR, et al. Prevalence of cirrhosis in

    patients with thrombocytopenia who receive bone marrow biopsy.

    Saudi J Gastroenterol. 2012;18(4):257–262.

    10. Wang CS, Yao WJ, Wang ST, et al. Strong association of hepatitis C

    virus (HCV) infection and thrombocytopenia: implications from a

    4
    survey of a community with hyperendemic HCV infection. Clin Infect

    Dis. 2004;39(6):790–796.

    11. Jaroszewicz J, Rogalska M, Flisiak R. Serum prohepcidin reflects the

    degree of liver function impairment in liver cirrhosis. Biomarkers.

    2008;13(5):478–485.

    12. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis

    of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost.

    2008;99(6):1019–1029.

    13. Uemura M, Fujimura Y, Ko S, et al. Pivotal role of ADAMTS13 func-

    tion in liver diseases. Int J Hematol. 2010;91(1):20–29.

    14. Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol

    Oncol Clin North Am. 2007;21(4):685–696, vi.

    15. Weksler BB. Review article: the pathophysiology of thrombocytopenia

    in hepatitis C virus infection and chronic liver disease. Aliment Phar-

    macol Ther. 2007;26(Suppl 1):13–19.

    16. George JN. Idiopathic thrombocytopenic purpura: current issues for

    pathogenesis, diagnosis, and management in children and adults. Curr

    Hematol Rep 2003;2:381–387.

    17. Perrotta PL, Snyder EL. Non-infectious complications of transfusion

    therapy. Blood Rev 2001;15:69–83.

    18. Cantor SB, Elting LS, Hudson Jr DV. Rubenstein EB.

    Pharmacoeconomic analysis of oprelvekin (recombinant human

    5
    interleukin-11) for secondary prophylaxis of thrombocytopenia in solid

    tumor patients receiving chemotherapy. Cancer 2003;97:3099–3106.

    19.

    You might also like